Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Palmoplantar pustular psoriasis for at least 6 months before Randomization
Moderate to severe palmoplantar pustular psoriasis as defined at Baseline by:
Candidate for systemic therapy, defined as having palmoplantar pustular psoriasis inadequately controlled by:
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
237 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal